WO2001040157A1 - Method for preparing chiral esters - Google Patents

Method for preparing chiral esters Download PDF

Info

Publication number
WO2001040157A1
WO2001040157A1 PCT/KR2000/001169 KR0001169W WO0140157A1 WO 2001040157 A1 WO2001040157 A1 WO 2001040157A1 KR 0001169 W KR0001169 W KR 0001169W WO 0140157 A1 WO0140157 A1 WO 0140157A1
Authority
WO
WIPO (PCT)
Prior art keywords
ester
preparing
chiral
group
ruthenium complex
Prior art date
Application number
PCT/KR2000/001169
Other languages
French (fr)
Inventor
Jai Wook Park
Mahn-Joo Kim
Jeong Hwan Koh
Hyun Min Jung
Original Assignee
Samsung Fine Chemicals Co., Ltd.
Pohang University Of Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Fine Chemicals Co., Ltd., Pohang University Of Science And Technology filed Critical Samsung Fine Chemicals Co., Ltd.
Priority to JP2001541847A priority Critical patent/JP2003515336A/en
Priority to EP00971838A priority patent/EP1237837A4/en
Priority to AU10587/01A priority patent/AU1058701A/en
Priority to CA002393336A priority patent/CA2393336A1/en
Publication of WO2001040157A1 publication Critical patent/WO2001040157A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Definitions

  • the present invention relates to a method for preparing a chiral ester and more particularly, the method for preparing an optically pure chiral ester from an alkenyl ester at a high yield by using an enzyme and a metal catalyst.
  • Kinetic resolution is the fact that the two enantiomers react at different rates with a chiral addend.
  • An effective kinetic resolution is the > eriantioselective conversion from a racemic mixture to an optically pure product (scheme 1), leaving the other enantiomer in the reaction mixture.
  • Burk's method introduced that a chrial ester having excellent optical purity was prepared from an alkenyl ester having both a carboxylic acid on ⁇ -position of C-C bond and electron deficient C-C bond and Zhang's method introduced that a chiral ester having excellent optical purity was prepared from a cyclic alkenyl ester. .1
  • these methods were applied to non-cyclic alkenyl esters, they showed low enantioselectivity.
  • an object of the present invention is to provide a simple 0 process for preparing optically pure chiral esters from various types of alkenyl esters at a high yield to resolve the above problems.
  • a process for preparing a chiral ester of the present invention is r> characterized by mixing and reacting: an alkenyl ester; a metallic complex, preferably ruthenium complex, more preferably ruthenium complex selected from the group consisting of compounds 1 and 2 expressed in formulas 1 and 2, to activate reduction reaction of said alkenyl ester and racemization; 0 a lipase to acylate selectively one of enantiomers of said alkenyl ester; and a reducing agent to supply a hydride to said ruthenium complex,
  • Yi, Y 2 , Y 3 , Y-i, Ys, Y ⁇ , Yz, Ys, Y9, Yio, Y11, and Y 12 are a hydrogen atom or a C1-C5 alkyl group;
  • X is Br, Cl or I; and
  • Q is H, Br, Cl, or I.
  • Ph is phenyl
  • Said ruthenium complex is selected from the group consisting of the compounds 3 to 5 expressed in the following formulas 3 to 5,
  • a method for preparing a chiral ester from an alkenyl ester is described as follows.
  • a mixture of a ruthenium complex selected from the group consisting of 7 formulas 1 and 2, a lipase, a reducing agent, and an alkenyl ester is reacted in an appropriate solvent in the presence of a base as shown in Scheme 2.
  • the reaction condition can be varied with a structure of ruthenium complex. For example, when the ruthenium complex of formula 3 where X is Cl and Q is Cl is used, the reaction is performed at a temperature of 40 to 50 ° C .
  • R 1 , R 2 and R 3 are, independently, optionally substituted alkyl, optionally substituted aryl or optionally substituted cycloalkyl group and R 1 and R 2 , R 1 and R 3 , and R 2 and R 3 can be cyclized each other, where said substituent of alkyl, aryl and cycloalkyl is a halogen atom or a cyano group.
  • Said lipase activates deacylation of an alkenyl ester which is a starting material to give the corresponding ketone.
  • Said ruthenium complex activates reduction reaction of the ketone to the corresponding alcohol by acting as a catalyst to transfer a hydrogen atom and further, activates racemization of the obtained alcohol.
  • Said lipase which is an ester hydrolase, acylates one enantiomer from racemic alcohol selectively to a chiral ester.
  • lipase are pseudomonas ccpacias lipase and Candida antarctica lipase, more preferablv, Candida antarctica component B lipase supported on acrylic resin (Novozvm 435, Novo company) or Pseudomonas cepacias lipase supported on ceramic particle (lipase PS-C, Amano company), the most preferably Candida antarctica component B lipase supported on acrylic resin for heat resistance, reactivity, optical purity and the like.
  • An amount of said lipase is in the range of 10 to 60mg, preferably 30 mg, relative to 1 mmol of alkenyl ester in Novozym 435 case, and is in the range of 40 to 240 mg, preferably 80 mg, relative to 1 mmol of alkenyl ester in lipase PS-C case.
  • Said alkenyl ester expressed by the formula 6 is not limited but it is preferred to use the following compounds 6a, 6b, 6c, 6d, 4e, 6f, 6g, or 6h.
  • Said reducing agent supplies a hydride to the ruthenium complex.
  • said reducing agent examples include 2,6-dimethylheptan-4-ol, hydrogen, and formic acid.
  • Preferred amount of said reducing agent is 1 to 2 equivalents to ⁇ equivalent to the alkenyl ester. If the content deviates from the range, it inhibits racemization reaction.
  • said reducing agent is hydrogen gas, it is preferred to be a pressure thereof in the range of 1 to 5 atmosphere. If the pressure is less than 1 atmosphere, the rate of the reduction becomes slow. On the other hand, if it is more than 5 atmospheres, it requires a high-pressure reactor.
  • a base is also required to remove an acid generated during the reaction.
  • Said base includes triethylamine or diisopropylethvl amine and preferred amount to use is in the range of 1 to 2 equivalents to 1 equivalent to the alkenyl ester.
  • Reaction solvent is not limited but it is preferred to use methylene chloride, toluene, benzene, or hexane because a solvent commonly affects production yield in an enzyme catalytic reaction.
  • An amount of said solvent is used to be 0.2 to 0.3 M concentration of the alkenyl ester.
  • a chiral ester expressed in formula 100 is obtained by reacting an alkenyl ester, a ruthenium complex, and a lipase, wherein R 1 , R 2 and R 3 are, independently, optionally substituted alkyl, optionally substituted aryl or optionally substituted cycloalkyl group and R 1 and R 2 , R 1 and R 3 , and R 2 and R 3 can be cyclized each other, where said substituent of alkyl, aryl and cycloalkyl is a halogen atom or a cyano group.
  • the chiral ester of formula 100 of the present invention can be used as a synthetic intermediate for preparing various chiral compounds, chiral pharmaceutical drugs or chiral agrochemicals and more particularly, used as an essential intermediate for preparing Atorvastatin expressed in formula 101 • which is a useful drug for treatment for hyperlipemia, L-Carnitine expressed in formula 102 which is as an additive used in food and cirugs, and Agenerase expressed in formula 103 which is an essential intermediate of AIDS drug.
  • a chiral compound of formula 100a which is one of the compounds of the present invention is a key intermediate for preparing
  • the process for preparing a chiral ester of formula 100 of the present invention provides minimum production of by-products such as unreacted alcohol residue up to less than 5% and maximum production of product up to 100% having a high optical purity of 99% or more. Because optical purity is 10 the most important factor in preparing chiral compounds for food and pharmaceutical drugs, the chiral ester of the present invention can be used as a useful starting material in various fields, especially in fine chemical field.
  • the product, chiral ester was prepared by the same procedure of Example 1 except to use an alkenyl ester of formulas 6b-6h instead of an alkenyl ester of formula 6a.
  • the product, chiral ester was prepared by the same procedure of Example 9 except to use an alkenyl ester of formulas 6b-4h instead of an alkenyl ester of formula 6a.
  • Oxygen was removed from the reaction suspension under the vacuum condition and further 1 atmosphere of hydrogen gas was injected and then it was heated at 70 ° C for 50 hours.
  • examples 1 to 8 and example 17 proved that the present invention provides one-step synthesis for preparing an optically pure chiral ester at a high yield from an alkenyl ester by controlling ruthenium complex and lipase. Further, an acyl donor compound is not used in the reaction at all.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to a method for preparing a chiral ester and more particularly, the method for preparing an optically pure chiral ester from an alkenyl ester at a high yield by mixing and reacting: an alkenyl ester; a ruthenium complex to activate reduction reaction of said alkenyl ester and racemization; a lipase to acylate selectively one of enantiomers of said alkenyl ester; and a reducing agent to supply a hydride to said ruthenium complex. Said optically pure chiral ester of the present invention can be prepared by one-step synthesis from various types of alkenyl esters at a high yield.

Description

METHOD FOR PREPARING CHIRAL ESTERS
BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to a method for preparing a chiral ester and more particularly, the method for preparing an optically pure chiral ester from an alkenyl ester at a high yield by using an enzyme and a metal catalyst.
It is one of important aims to convert a racemic mixture to an opticallv pure compound enantioselectively in organic synthesis. Recently, studies for using a metal or an enzyme as a catalyst have been increased in asvmmetric syntheses. It has been widely known to use an enzyme as a catalyst for kinetic resolution of a racemic mixture in organic syntheses.
Kinetic resolution is the fact that the two enantiomers react at different rates with a chiral addend. An effective kinetic resolution is the > eriantioselective conversion from a racemic mixture to an optically pure product (scheme 1), leaving the other enantiomer in the reaction mixture.
Scheme 1
OH OH LiPase QAc OH
: I Acyl donor : + I
Rj^^Rz RY"^R2 *~ Rι"^R2 R f ^R ?
Conventional methods for preparing a chiral ester from an alkenvl ester are usually by asymmetric hydrogenation using a catalyst (Mark J. Burk, C. S. Kalberg, and A. Pizzano, /. Am. Chem. Soc. 1998, 120, 4345 and Q. Jiang, Xiao, Z. Zhang, P. Cao and Xumu Zhang, Angew. Cliem. Int. Ed. Engl. 1999, 38, 516). Among these asymmetric hydrogenations, Burk's method introduced that a chrial ester having excellent optical purity was prepared from an alkenyl ester having both a carboxylic acid on α-position of C-C bond and electron deficient C-C bond and Zhang's method introduced that a chiral ester having excellent optical purity was prepared from a cyclic alkenyl ester. .1 However, when these methods were applied to non-cyclic alkenyl esters, they showed low enantioselectivity.
SUMMARY OF THE INVENTION
Therefore, an object of the present invention is to provide a simple 0 process for preparing optically pure chiral esters from various types of alkenyl esters at a high yield to resolve the above problems.
Detailed Description of the Invention
A process for preparing a chiral ester of the present invention is r> characterized by mixing and reacting: an alkenyl ester; a metallic complex, preferably ruthenium complex, more preferably ruthenium complex selected from the group consisting of compounds 1 and 2 expressed in formulas 1 and 2, to activate reduction reaction of said alkenyl ester and racemization; 0 a lipase to acylate selectively one of enantiomers of said alkenyl ester; and a reducing agent to supply a hydride to said ruthenium complex,
Figure imgf000003_0001
wherein Yi, Y2, Y3, Y-i, Ys, Yβ, Yz, Ys, Y9, Yio, Y11, and Y12 are a hydrogen atom or a C1-C5 alkyl group; X is Br, Cl or I; and Q is H, Br, Cl, or I.
Figure imgf000004_0001
wherein Ph is phenyl.
Said ruthenium complex is selected from the group consisting of the compounds 3 to 5 expressed in the following formulas 3 to 5,
Figure imgf000004_0002
Among the compounds of formulas 3 to 5, a compound of formulas 3a or 3b wherein X is Cl and Q is H or Cl is more preferable,
Figure imgf000004_0003
Figure imgf000005_0001
A method for preparing a chiral ester from an alkenyl ester is described as follows.
A mixture of a ruthenium complex selected from the group consisting of 7 formulas 1 and 2, a lipase, a reducing agent, and an alkenyl ester is reacted in an appropriate solvent in the presence of a base as shown in Scheme 2. The reaction condition can be varied with a structure of ruthenium complex. For example, when the ruthenium complex of formula 3 where X is Cl and Q is Cl is used, the reaction is performed at a temperature of 40 to 50 °C . When the
10 ruthenium complex of formula 3 where X is Cl and Q is H is used, the reaction is performed at a temperature of 40 to 50 °C . When the ruthenium complex of formula 2 where X is Cl and Q is Cl is used, the reaction requires 70 to 80 °C of a reaction temperature. The ruthenium complex of formula 3 where X is Cl and Q is Cl is commercially available and is converted to the ruthenium complex of
I T) formula 3 where X is Cl and Q is H in alcohol/ amine base condition. Therefore, results from the ruthenium complex of formula 5 and the ruthenium complex of formula 8 are almost same. A content of said ruthenium complex is preferred to use 0.1 to 5 mol%, relative to an alkenyl ester. If the content is more than 5 mol%, cost becomes expensive. On the other hand, if it is less
20 than 0.1 mol%, the rate of the reaction becomes too slow. Scheme 2
Figure imgf000006_0001
wherein R1, R2 and R3 are, independently, optionally substituted alkyl, optionally substituted aryl or optionally substituted cycloalkyl group and R1 and R2, R1 and R3, and R2 and R3 can be cyclized each other, where said substituent of alkyl, aryl and cycloalkyl is a halogen atom or a cyano group.
Said lipase activates deacylation of an alkenyl ester which is a starting material to give the corresponding ketone.
Said ruthenium complex activates reduction reaction of the ketone to the corresponding alcohol by acting as a catalyst to transfer a hydrogen atom and further, activates racemization of the obtained alcohol.
Said lipase, which is an ester hydrolase, acylates one enantiomer from racemic alcohol selectively to a chiral ester. Examples of lipase are pseudomonas ccpacias lipase and Candida antarctica lipase, more preferablv, Candida antarctica component B lipase supported on acrylic resin (Novozvm 435, Novo company) or Pseudomonas cepacias lipase supported on ceramic particle (lipase PS-C, Amano company), the most preferably Candida antarctica component B lipase supported on acrylic resin for heat resistance, reactivity, optical purity and the like. An amount of said lipase is in the range of 10 to 60mg, preferably 30 mg, relative to 1 mmol of alkenyl ester in Novozym 435 case, and is in the range of 40 to 240 mg, preferably 80 mg, relative to 1 mmol of alkenyl ester in lipase PS-C case.
Said alkenyl ester expressed by the formula 6 is not limited but it is preferred to use the following compounds 6a, 6b, 6c, 6d, 4e, 6f, 6g, or 6h.
Figure imgf000007_0001
Figure imgf000007_0002
Figure imgf000007_0003
Figure imgf000007_0004
Figure imgf000007_0005
Figure imgf000007_0006
Figure imgf000007_0007
Figure imgf000008_0001
Said reducing agent supplies a hydride to the ruthenium complex.
Examples of said reducing agent are 2,6-dimethylheptan-4-ol, hydrogen, and formic acid. Preferred amount of said reducing agent is 1 to 2 equivalents to Λ equivalent to the alkenyl ester. If the content deviates from the range, it inhibits racemization reaction. When said reducing agent is hydrogen gas, it is preferred to be a pressure thereof in the range of 1 to 5 atmosphere. If the pressure is less than 1 atmosphere, the rate of the reduction becomes slow. On the other hand, if it is more than 5 atmospheres, it requires a high-pressure reactor.
A base is also required to remove an acid generated during the reaction. Said base includes triethylamine or diisopropylethvl amine and preferred amount to use is in the range of 1 to 2 equivalents to 1 equivalent to the alkenyl ester.
Reaction solvent is not limited but it is preferred to use methylene chloride, toluene, benzene, or hexane because a solvent commonly affects production yield in an enzyme catalytic reaction. An amount of said solvent is used to be 0.2 to 0.3 M concentration of the alkenyl ester.
A chiral ester expressed in formula 100 is obtained by reacting an alkenyl ester, a ruthenium complex, and a lipase,
Figure imgf000009_0001
wherein R1, R2 and R3 are, independently, optionally substituted alkyl, optionally substituted aryl or optionally substituted cycloalkyl group and R1 and R2, R1 and R3, and R2 and R3 can be cyclized each other, where said substituent of alkyl, aryl and cycloalkyl is a halogen atom or a cyano group.
The chiral ester of formula 100 of the present invention can be used as a synthetic intermediate for preparing various chiral compounds, chiral pharmaceutical drugs or chiral agrochemicals and more particularly, used as an essential intermediate for preparing Atorvastatin expressed in formula 101 •which is a useful drug for treatment for hyperlipemia, L-Carnitine expressed in formula 102 which is as an additive used in food and cirugs, and Agenerase expressed in formula 103 which is an essential intermediate of AIDS drug.
Figure imgf000009_0002
+ OH O Me,N. 1
(102)
Figure imgf000009_0003
Especially, a chiral compound of formula 100a which is one of the compounds of the present invention is a key intermediate for preparing
Atorvastatin of formula 101 disclosed in US Patent No. 5,908,953,
OH O
NCY Y\ Y^
(100a)
." -wherein R is a low alkyl group.
The process for preparing a chiral ester of formula 100 of the present invention provides minimum production of by-products such as unreacted alcohol residue up to less than 5% and maximum production of product up to 100% having a high optical purity of 99% or more. Because optical purity is 10 the most important factor in preparing chiral compounds for food and pharmaceutical drugs, the chiral ester of the present invention can be used as a useful starting material in various fields, especially in fine chemical field.
The following examples are intended to be illustrative of the present 1.1 invention and should not be construed as limiting the scope of this invention defined by the appended claims.
Example 1
1-Phenylethenyl acetate of formula 6a(1.00mmol), ruthenium complex 20 of formula 2 (0.020mmol), 2,6-dimethylheptan-4-ol(1.50mmol), and 28mg of a lipase Nozyme-435 were added to 3.0ml of toluene. The reaction mixture was stirred to give a yellow suspension.
Argon gas was purged into the reaction suspension, after removing an oxygen under the vacuum condition and then the suspension was heated at 27 70 °C for 42 hours. After evaporating a solvent from the reaction mixture, the residue was purified by column chromatography on silica gel to obtain 139mg of 1-(1- phenylethyl)acetate.
Examples 2 to 8
The product, chiral ester, was prepared by the same procedure of Example 1 except to use an alkenyl ester of formulas 6b-6h instead of an alkenyl ester of formula 6a.
Example 9
The product, chiral ester, was prepared by the same procedure of Example 1 except to use ruthenium complex, where X is Cl and Q is Cl, of formula 3 instead ruthenium complex of formula 2.
Examples 10 to 16
The product, chiral ester, was prepared by the same procedure of Example 9 except to use an alkenyl ester of formulas 6b-4h instead of an alkenyl ester of formula 6a.
Example 17
1-Phenylethenyl acetate of formula 6a(1.00mmol), ruthenium complex of formula 2 where (0.020mmol), and 28mg of Nozyme 435 were added to 3.0ml of toluene and stirred to give a yellow suspension.
Oxygen was removed from the reaction suspension under the vacuum condition and further 1 atmosphere of hydrogen gas was injected and then it was heated at 70 °C for 50 hours.
After evaporating a solvent from the reaction mixture, the residue was purified by column chromatography on silica gel to obtain 141mg of 1-(1- phenylethyl)acetate.
In examples 1 to 8 and example 17 to prepare chiral esters, yield and optical purity of chiral acetates were determined and tabled in Table 1. Said yield of chiral acetate was analyzed by gas chromatography, and saici optical purity was determined by high performance liquid chromatography. Said gas chromatography used was Hewlett Packard 5890 Series II and said high performance liquid chromatography was SpectraSystem P2000.
Table 1
Figure imgf000012_0001
As shown in Table 1, examples 1 to 8 and example 17 proved that the present invention provides one-step synthesis for preparing an optically pure chiral ester at a high yield from an alkenyl ester by controlling ruthenium complex and lipase. Further, an acyl donor compound is not used in the reaction at all.

Claims

CLAIMS What is claimed is:
1. A process for preparing a chiral ester expressed in formula 100 by mixing and reacting: 5 art alkenyl ester expressed by formula 6; a ruthenium complex selected from the group consisting of compounds 1 and 2 expressed in formulas 1 and 2 to activate reduction reaction of said alkenyl ester and racemization; a lipase to acylate selectively one of enantiomers of said alkenyl ester; and () a reducing agent to supply a hydride to said ruthenium complex,
Figure imgf000014_0001
wherein Yi, Y2, Y3, Y4, Y5, Yβ, Y7, Ys, Y9, Yio, Y11, and Yι2 are a hydrogen atom or C1-C5 alkyl group; X is Br, Cl or I; and Q is H, Br, Cl, or I.
Figure imgf000014_0002
wherein Ph is phenyl.
Figure imgf000014_0003
Figure imgf000015_0001
wherein R1, R2 and R3 are, independently, optionally substituted alkyl, optionally substituted aryl or optionally substituted cycloalkyl group and R1 and R2, R1 and R3, and R2 and R3 can be cyclized each other, where said substituent of alkyl, aryl and cycloalkyl is a halogen atom or a cyano group.
2. The process for preparing a chiral ester according to claim 1, wherein said alkenyl ester is selected from the group consisting of the compounds of formulas 6a to 6h,
Figure imgf000015_0002
Figure imgf000015_0003
Figure imgf000015_0004
Figure imgf000015_0005
Figure imgf000016_0001
Figure imgf000016_0002
Figure imgf000016_0003
3. The process for preparing a chiral ester according to claim 1, wherein said ruthenium complex is selected from the group consisting of compounds of formulas 3, 4, and 5,
Figure imgf000016_0004
wherein X is Cl, Br or I; and Q is H, Br, Cl or I.
4. The process for preparing a chiral ester according to claim 3, wherein X is Cl and Q is H or Cl for said compound of formulas 3 to 5.
5. The process for preparing a chiral ester according to claim 1, wherein said lipase is selected from the group consisting of Pseudomonas cepacias lipase and Candida antarctica component B lipase.
6. The process for preparing a chiral ester according to claim 1, wherein said reducing agent is selected from the group consisting of 2,6-dimethylhepthan-4- ol, hydrogen and formic acid.
7. The process for preparing a chiral ester according to claim 1, wherein a content of said ruthenium complex is in the range of 0.1 to 5 mol%, relative to said alkenyl ester.
15
PCT/KR2000/001169 1999-12-02 2000-10-18 Method for preparing chiral esters WO2001040157A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001541847A JP2003515336A (en) 1999-12-02 2000-10-18 Method for producing chiral ester
EP00971838A EP1237837A4 (en) 1999-12-02 2000-10-18 Method for preparing chiral esters
AU10587/01A AU1058701A (en) 1999-12-02 2000-10-18 Method for preparing chiral esters
CA002393336A CA2393336A1 (en) 1999-12-02 2000-10-18 Method for preparing chiral esters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1999-54472 1999-12-02
KR19990054472 1999-12-02

Publications (1)

Publication Number Publication Date
WO2001040157A1 true WO2001040157A1 (en) 2001-06-07

Family

ID=19623196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2000/001169 WO2001040157A1 (en) 1999-12-02 2000-10-18 Method for preparing chiral esters

Country Status (7)

Country Link
US (1) US6475773B2 (en)
EP (1) EP1237837A4 (en)
JP (1) JP2003515336A (en)
CN (1) CN1390189A (en)
AU (1) AU1058701A (en)
CA (1) CA2393336A1 (en)
WO (1) WO2001040157A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100462473B1 (en) * 2002-10-31 2004-12-17 학교법인 포항공과대학교 Method for the preparation of chiral hydroxy esters by enzyme-metal multi-catalysis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280429A1 (en) * 2008-05-08 2009-11-12 Xerox Corporation Polyester synthesis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375417A2 (en) * 1988-12-22 1990-06-27 Takasago International Corporation Process for preparing optically active carnitine ester
EP0992481A1 (en) * 1998-10-02 2000-04-12 Basf Aktiengesellschaft Process for the asymmetric hydrogenation of beta-ketoesters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375417A2 (en) * 1988-12-22 1990-06-27 Takasago International Corporation Process for preparing optically active carnitine ester
EP0992481A1 (en) * 1998-10-02 2000-04-12 Basf Aktiengesellschaft Process for the asymmetric hydrogenation of beta-ketoesters

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUSAN HSEK ET AL.: "Novel synthetic routes to several new, differentially substituted ruthenium tris(4,4'-disubstituted-2,2-bipyridine) complexes", AMERICAN CHEMICAL SOCIETY, vol. 39, no. 2, 2000, pages 308 - 316, XP002956926 *
FUJII AKIO ET AL.: "Ruthenium(2)-catalyzed asymmetric transfer hydrogenation of ketones using a formic acid-triethylamine mixture", AMERICAN CHEMICAL SOCIETY, vol. 110, no. 10, 1996, pages 2521 - 2522, XP002092424 *
MASUTANI K. ET AL.: "Catalytic asymmetric and chemoselective aerobic oxidation: Kinetic resolution of sec-alcohols", TETRAHEDRON LETTERS, vol. 41, no. 26, 2000, pages 5119 - 5123, XP004212511 *
NORIKO DODO ET AL.: "Synthesis of ruthenium complexes with planar-chiral cyclopentadienyl-pyridine or -phosphine bidentate ligands", ROYAL SOCIETY OF CHEMISTRY, vol. 1, 2000, DALTON, pages 35 - 41, XP002956927 *
See also references of EP1237837A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100462473B1 (en) * 2002-10-31 2004-12-17 학교법인 포항공과대학교 Method for the preparation of chiral hydroxy esters by enzyme-metal multi-catalysis

Also Published As

Publication number Publication date
US6475773B2 (en) 2002-11-05
US20010012898A1 (en) 2001-08-09
EP1237837A1 (en) 2002-09-11
CN1390189A (en) 2003-01-08
CA2393336A1 (en) 2001-06-07
EP1237837A4 (en) 2003-04-16
JP2003515336A (en) 2003-05-07
AU1058701A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
Tan et al. Enzymatic resolution coupled with substrate racemization using a thioester substrate
JPS63273499A (en) Production of optically active compound
WO2005073388A1 (en) Processes for producing optically active 1-substituted 2-methylpyrrolidine and intermediate therefor
US6753443B1 (en) Preparing method of chiral ester
Arosio et al. Chemo‐enzymatic dynamic kinetic resolution of amino acid thioesters
WO2001040157A1 (en) Method for preparing chiral esters
EP2203562B1 (en) Process for the preparation of an enantiomerically and/or diastereomerically enriched ester, thioester, alcohol or thiol
Shi-Hui et al. Synthesis of enantiomerically pure cycloalkenols via combination strategy of enzyme-catalyzed reaction and RCM reaction
US7582469B2 (en) Method for enantioselectively opening oxetan-2-ones
US7156731B2 (en) Resolution of chiral compounds using aminocyclopentadienyl ruthenium catalysts
WO2007078176A1 (en) The method of making optically active 2-chloromandelic acid esters and 2-chloromandelic acids by enzymatic method
EP1226105A1 (en) Method for preparing chiral ester
KR100402036B1 (en) Method for preparing chiral ester
EP1290208B1 (en) Method for optically resolving a racemic alpha-substituted heterocyclic carboxylic acid using enzyme
KR19990082197A (en) Method for preparing optically active amines
WO2001092554A1 (en) Method for preparing an r- or s-form of alpha-substituted heterocyclic carboxylic acid and a counter enantiomeric form of alpha-substituted heterocyclic carboxylic acid ester thereto using enzyme
KR100657204B1 (en) The method of making optically active 3-hydroxy-?-butyrolactone by enzymatic method
KR100359028B1 (en) Method for preparing chiral allyl ester
JP2005506091A (en) Process for the production of (R)-and (S) -8-chloro-6-hydroxy-octanoic acid alkyl esters by enzymatic reduction
JPH0751077A (en) Preparation of l-alpha - amino acid
WO2008009710A1 (en) Process for the production of fluorine containing alpha-hydroxy carboxylic acids
JP2006014636A (en) Method for producing acyl derivative
WO2004039998A1 (en) Method for the preparation of chiral hydroxy esters by enzyme/metal multi-catalysis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00343/DE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2001 541847

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008157855

Country of ref document: CN

Ref document number: 2000971838

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2393336

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000971838

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000971838

Country of ref document: EP